4-n-pentylbenzamide | 138913-07-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-n-pentylbenzamide
• 英文别名: 4-pentylbenzamide；4-pentyl-benzoic acid amide；4-Pentyl-benzoesaeure-amid
• CAS: 138913-07-2
• 化学式: C₁₂H₁₇NO
• mdl: MFCD00984217
• 分子量: 191.273
• InChiKey: IQBKZMNCFRIQRR-UHFFFAOYSA-N

物化性质

• 沸点：
  324.6±21.0 °C(Predicted)
• 密度：
  1.004±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  4-n-pentylbenzamide 在 劳森试剂 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 1-[4-methyl-2-(4-pentylphenyl)thiazol-5-yl]ethanone
  参考文献：
  名称：

  Discovery and Characterization of Potent Thiazoles versus Methicillin- and Vancomycin-Resistant Staphylococcus aureus

  摘要：

  Methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) infections are growing global health concerns. Structure-activity relationships of phenylthiazoles as a new antimicrobial class have been addressed. We present 10 thiazole derivatives that exhibit strong activity against 18 clinical strains of MRSA and VRSA with acceptable PK profile. Three derivatives revealed an advantage over vancomycin by rapidly eliminating MRSA growth within 6 h, and no derivatives are toxic to HeLa cells at 11 mu g/mL.

  DOI：

  10.1021/jm401905m
• 作为产物：
  描述：

  4-正戊基苯甲酸 在 ammonium hydroxide 、 氯化亚砜 作用下， 以 水 为溶剂， 反应 2.0h， 生成 4-n-pentylbenzamide
  参考文献：
  名称：

  Discovery and Characterization of Potent Thiazoles versus Methicillin- and Vancomycin-Resistant Staphylococcus aureus

  摘要：

  Methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) infections are growing global health concerns. Structure-activity relationships of phenylthiazoles as a new antimicrobial class have been addressed. We present 10 thiazole derivatives that exhibit strong activity against 18 clinical strains of MRSA and VRSA with acceptable PK profile. Three derivatives revealed an advantage over vancomycin by rapidly eliminating MRSA growth within 6 h, and no derivatives are toxic to HeLa cells at 11 mu g/mL.

  DOI：

  10.1021/jm401905m

文献信息

• Compounds Which Modulate The CB2 Receptor
  申请人：Berry Angela

  公开号：US20100009964A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) are disclosed. Compounds according to the and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  公式（I）的化合物已被披露。根据该公式的化合物对治疗炎症有用。那些是激动剂的化合物还额外适用于治疗疼痛。
• INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE
  申请人：Hurley Timothy Brian

  公开号：US20090325948A1

  公开（公告）日：2009-12-31

  The present invention relates to compounds that are selective and/or potent inhibitors of UPPS. In addition to compounds which inhibit UPPS, the invention also provides pharmaceutical compositions comprising these compounds and methods of using these compounds for treating bacterial disease, such as bacterial infection.

  本发明涉及选择性和/或有效抑制UPPS的化合物。除了抑制UPPS的化合物外，本发明还提供包含这些化合物的药物组合物以及使用这些化合物治疗细菌性疾病，如细菌感染的方法。
• Imidazolyl inhibitors of 15-lipoxygenase
  申请人：Weinstein S. David

  公开号：US20050070588A1

  公开（公告）日：2005-03-31

  The present invention provides imidazolyl inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.

  本发明提供了15-LO的咪唑基抑制剂，包含这些抑制剂的药物组合物以及使用这些化合物和组合物治疗与15-LO级联相关疾病的方法。
• Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
  申请人：Pregel J. Marko

  公开号：US20050176761A1

  公开（公告）日：2005-08-11

  Tetrhydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.

  本文披露了四氢异喹啉衍生物、包含它们的药物组合物以及治疗疾病的方法。所披露的化合物在治疗和预防由氯离子通道活性和/或蛋白质运输介导的疾病方面是有用的，包括但不限于与黏液纤毛清除受损有关的疾病，如囊性纤维化、支气管炎、肺气肿等。
• [EN] SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS<br/>[FR] AMINOALKYLAZOLES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PROTÉASE ASPARTIQUE DU PALUDISME
  申请人：LATVIAN INST ORGANIC SYNTHESIS

  公开号：WO2017069601A1

  公开（公告）日：2017-04-27

  The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.

  本发明涉及作为疟疾蛋白酶质体酶II抑制剂的新型氨基烷基唑类化合物。这些化合物可用作治疗疟疾感染的药物或药物成分。